This study demonstrates the protective effects of a novel synbiotic, β-glucan and Lactobacillus johnsonii, in ulcerative colitis, indicating its potential as a new therapeutic option.
Key Points
BGLJ treatment significantly mitigated DSS-induced weight loss and reduced disease activity.
Notably, BGLJ markedly increased Lactobacillus johnsonii populations in fecal samples.